Boston Scientific(US:BSX) Globenewswire·2026-03-09 20:00Core Viewpoint - Boston Scientific Corporation is facing a class action securities lawsuit due to alleged securities fraud that affected investors between July 23, 2025, and February 3, 2026 [1] Group 1: Lawsuit Details - The lawsuit claims that Boston Scientific's management provided overly positive statements while concealing material adverse facts about the U.S. electrophysiology (EP) segment, including the unsustainable growth rate and an earlier-than-expected tipping point [2] - Following the release of disappointing fourth quarter and full year 2025 results, including a significant miss in U.S. EP sales, the company issued guidance for fiscal 2026 that was well below market expectations [2] - On February 4, 2026, Boston Scientific's stock price dropped from $91.62 to $75.50, a decline of approximately 17.6% in one day, following the negative news [2] Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until May 4, 2026, to request to be appointed as lead plaintiff in the lawsuit [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]